Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20230285441TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
US 14.09.2023
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
Appl.No 17996318 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor Mukesh Kumar

The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.

2.WO/2021/173592SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF
WO 02.09.2021
Int.Class A61K 31/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
Appl.No PCT/US2021/019295 Applicant MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor WENDEL, Hans-Guido
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus [SARS-CoV], severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2, the virus and its mutant forms that cause COVID-19], Middle East respiratory syndrome coronavirus [MERS-CoV]), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
3.WO/2022/008971TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO
WO 13.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/IB2021/000460 Applicant COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL (CCSS) Inventor MACAYA HAYES, Roman, Federico
Methods and compositions for treating a severe acute respiratory syndrome- related coronavirus (SARS-CoV) infection in a subject in need are provided. In some aspects, a therapeutically effective amount of a Klotho polypeptide and/or a Klotho polynucleotide encoding a Klotho polypeptide is administered to the subject. In some other aspects, the subject is treated with a first therapy when the subject has diminished Klotho activity, and with a second therapy when the subject does not have diminished Klotho activity. Diminished Klotho activity is determined by comparing the amount of Klotho protein in a blood sample from the subject to a predetermined threshold. In particular, methods and compositions for treating SARS-CoV-2 infection are provided.
4.WO/2022/248733USE OF ESTETROL IN TREATMENT OF RESPIRATORY INFECTION DISEASES
WO 01.12.2022
Int.Class A61K 31/565
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Appl.No PCT/EP2022/064550 Applicant NEURALIS SA Inventor FOIDART, Jean-Michel
The present invention relates to the use of an effective amount of estetrol component to treat respiratory infection diseases such as those caused by severe acute respiratory syndrome-related viruses, for example Coroniviridae such as SARS-CoV, MERS-CoV or SARS-CoV-2 (COVID-19), optionally in combination with conventional treatment strategies for said diseases. The invention particularly relates to the use of an effective amount of estetrol component for reducing cytokine expression levels and/or reducing the risk of blot clots in subjects that may be diagnosed with, or are considered to have a respiratory infection disease such as SARS-related diseases. Estetrol components such as those described by the present invention have a beneficial effect on the prognosis of respiratory disease progression and the recovery rate of the afflicted subjects.
5.WO/2023/170187INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
WO 14.09.2023
Int.Class A61K 31/4418
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4418having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
Appl.No PCT/EP2023/055949 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor PICHLMAIR, Andreas
The invention refers to an inhibitor of the IκB kinase-α (IKK-α)/ NF-κB-inducing kinase (NIK) complex for use in preventing or treating infection, in particular viral or bacterial infection in a cell and/or subject, in particular for preventing or treating SARS-CoV-2 infection in a subject and/or for use in preventing or treating coronavirus disease 2019 (COVID-19) in a subject. Corresponding pharmaceutical compositions are also contemplated.
6.20230357366Antigen Binding Molecules Targeting SARS-CoV-2
US 09.11.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 18313306 Applicant Generate Biomedicines, Inc. Inventor Francesco Borriello

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

7.20230120864TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY
US 20.04.2023
Int.Class A61K 31/737
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
Appl.No 17910220 Applicant Sydney David Cullis-Hill Inventor Sydney David Cullis-Hill

The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine-associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2.

8.20230357367Antigen Binding Molecules Targeting SARS-CoV-2
US 09.11.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 18314091 Applicant Generate Biomedicines, Inc. Inventor Francesco Borriello

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

9.WO/2022/189379TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS
WO 15.09.2022
Int.Class A61K 31/136
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
136having the amino group directly attached to the aromatic ring, e.g. benzeneamine
Appl.No PCT/EP2022/055794 Applicant TECHNISCHE UNIVERSITÄT MÜNCHEN Inventor PICHLMAIR, Andreas
The invention refers to an inhibitor of at least one S-adenosylmethionine (SAM) cycle enzyme for use in preventing or treating coronavirus disease 2019 (COVID-19) in a subject, or for use in preventing or treating of infection with severe acute respiratory syndrome coronavirus-2 (SARS- CoV-2) in a subject, wherein the at least one SAM cycle enzyme is selected from the group consisting of methionine adenosyltransferase, betaine-homocysteine methyltransferase, methionine synthase, methionine synthase reductase and S-adenosylhomocys.
10.20230192872TOCILIZUMAB FOR THE TREATMENT OF VIRAL INFECTIONS
US 22.06.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17995225 Applicant The University of Chicago Inventor Mark J. RATAIN

Provided herein are methods for the treatment of viral infections and inflammation secondary to viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of low doses of tocilizumab to a subject. In particular embodiments, provided herein are pharmaceutical compositions comprising doses of 200 mg or less of tocilizumab and methods for the treatment of SARS-CoV-2 infections, COVID-19, inflammation secondary to such infections, and symptoms or other conditions arising as a result thereof.